

Recombinant Human CD30/TNFRSF8 Protein (His & Avi Tag)

Catalog No. PKSH033791

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	Tumor necrosis factor receptor superfamily member 8;CD30L receptor;Ki-1 antigen;Lymphocyte activation antigen CD30;CD30;TNFRSF8;D1S166E
Species	Human
Expression Host	HEK293 Cells
Sequence	Phe19-Lys379
Accession	P28908
Calculated Molecular Weight	41.1 kDa
Observed molecular weight	60-90 kDa
Tag	C-His-Avi
Bioactivity	Not validated for activity

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 µm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

CD30; also known as TNFRSF8; is a cell membrane protein of the tumor necrosis factor receptor family; which regulates

For Research Use Only

proliferation/apoptosis and antibody responses. CD30 is expressed by activated; but not by resting; T and B cells. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. CD30 has been considered as a specific diagnostic biomarker of anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (cHL). CD30 is also a biomarker used for targeted therapy by an antibody–drug conjugate.